(Q38084470)

28 August 2017

Anaemia management and mortality risk in chronic kidney disease (English)

1 reference

28 August 2017

Walter H Hörl

1

1 reference

PubMed ID

23438972

28 August 2017

language of work or name

English

0 references

publication date

26 February 2013

1 reference

Nature Reviews Nephrology

28 August 2017

1 reference

28 August 2017

9

1 reference

28 August 2017

5

1 reference

28 August 2017

291-301

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneph.2013.21

28 August 2017

0 references

cites work

Erythropoietic stimulating agents and quality of a patient's life: individualizing anemia treatment.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

A physician's perseverance uncovers problems in a key nephrology study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Against TREATing all patients alike: lessons from an FDA Advisory Committee Meeting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Stroke in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia treated with Darbepoetin Alfa: the trial to reduce cardiovascular events with Aranesp therapy (TREAT) experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Predictors of fatal and nonfatal cardiovascular events in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia: An analysis of the Trial to Reduce cardiovascular Events with Aranesp (darbepoetin-alfa) Therapy (TREAT)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

The new FDA labeling for ESA--implications for patients and providers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Darbepoetin alfa impact on health status in diabetes patients with kidney disease: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Changing patterns of anemia management in US hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Comparative mortality risk of anemia management practices in incident hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Positive outcomes of high hemoglobin target in patients with chronic kidney disease not on dialysis: a randomized controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Allosensitization rate of male patients awaiting first kidney grafts after leuko-depleted blood transfusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Prospective evaluation of pretransplant blood transfusions in cadaver kidney recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Reducing versus discontinuing erythropoietin at high hemoglobin levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Association of hemoglobin variability and mortality among contemporary incident hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Hemoglobin variability does not predict mortality in European hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Between subjects variability in haemoglobin and dose are not associated with the erythropoiesis-stimulating agent used to treat anaemia in dialysis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Mortality in renal transplant recipients given erythropoietins to increase haemoglobin concentration: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Naturally occurring higher hemoglobin concentration does not increase mortality among hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoietin, iron depletion, and relative thrombocytosis: a possible explanation for hemoglobin-survival paradox in hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Anemia management and association of race with mortality and hospitalization in a large not-for-profit dialysis organization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Effect of Epoetin alfa dose changes on hemoglobin and mortality in hemodialysis patients with hemoglobin levels persistently below 11 g/dL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Estimated effect of epoetin dosage on survival among elderly hemodialysis patients in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Relationship between epoetin alfa dose and mortality: findings from a marginal structural model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Dose of erythropoiesis-stimulating agents and adverse outcomes in CKD: a metaregression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Exploring relative mortality and epoetin alfa dose among hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Impact of higher hemoglobin targets on blood pressure and clinical outcomes: a secondary analysis of CHOIR

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Predictors of haemoglobin levels and resistance to erythropoiesis-stimulating agents in patients treated with low-flux haemodialysis, haemofiltration and haemodiafiltration: results of a multicentre randomized and controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Anemia and anemia correction: surrogate markers or causes of morbidity in chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Relationship between eicosanoids and endothelin-1 in the pathogenesis of erythropoietin-induced hypertension in uremic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoietin upregulates angiotensin receptors in cultured rat vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Involvement of erythropoietin-induced cytosolic free calcium mobilization in activation of mitogen-activated protein kinase and DNA synthesis in vascular smooth muscle cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Mechanism of erythropoietin-induced hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

The DOPPS Practice Monitor for US dialysis care: trends through August 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Ferric gluconate reduces epoetin requirements in hemodialysis patients with elevated ferritin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Administration of parenteral iron and mortality among hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Serum iron markers are inadequate for guiding iron repletion in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Hemodialysis-associated hemosiderosis in the era of erythropoiesis-stimulating agents: a MRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

The fascinating but deceptive ferritin: to measure it or not to measure it in chronic kidney disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

New erythropoiesis-stimulating agents and new iron formulations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Clinical aspects of iron use in the anemia of kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

A review of safety, efficacy, and utilization of erythropoietin, darbepoetin, and peginesatide for patients with cancer or chronic kidney disease: a report from the Southern Network on Adverse Reactions (SONAR).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

High Target Hemoglobin With Erythropoiesis-Stimulating Agents Has Advantages in the Renal Function of Non-Dialysis Chronic Kidney Disease Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Associations between Changes in Hemoglobin and Administered Erythropoiesis-Stimulating Agent and Survival in Hemodialysis Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin

21 January 2018

2 references

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

21 January 2018

12 December 2020

Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Nutritional-inflammation status and resistance to erythropoietin therapy in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Haemoglobin at time of referral prior to dialysis predicts survival: an association of haemoglobin with long-term outcomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Correction of anemia with epoetin alfa in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Differentiating factors between erythropoiesis-stimulating agents: an update to selection for anaemia of chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. Canadian Erythropoietin Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

An Economic Evaluation of Erythropoiesis-Stimulating Agents in CKD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoiesis-stimulating agents--time for a reevaluation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Does TREAT give the boot to ESAs in the treatment of CKD anemia?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Anemia management in chronic kidney disease: bursting the hemoglobin bubble

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

The controversy surrounding hemoglobin and erythropoiesis-stimulating agents: what should we do now?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

What caused excess strokes in patients randomized to darbepoetin in the trial to reduce cardiovascular events with Aranesp therapy (TREAT)?: no smoking gun

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Effect of red cell transfusions on future kidney transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Effect of perioperative blood transfusions on long term graft outcomes in renal transplant patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Facility-level interpatient hemoglobin variability in hemodialysis centers participating in the Dialysis Outcomes and Practice Patterns Study (DOPPS): Associations with mortality, patient characteristics, and facility practices

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Greater Epoetin alfa (EPO) doses and short-term mortality risk among hemodialysis patients with hemoglobin levels less than 11 g/dL

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Impact of rHuEPO therapy initiation on soluble adhesion molecule levels in haemodialysis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Normalization of hematocrit in hemodialysis patients with cardiac disease does not increase blood pressure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Clinical Practice Guidelines for supplemental therapies and issues

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Bundled payment for ESRD--including ESAs in Medicare's dialysis package

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

It's time to compare anemia management strategies in hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

A randomized controlled trial of oral heme iron polypeptide versus oral iron supplementation for the treatment of anaemia in peritoneal dialysis patients: HEMATOCRIT trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEPH.2013.21

Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans

31 March 2020

1 reference

12 December 2020

Resolved: Targeting a higher hemoglobin is associated with greater risk in patients with CKD anemia: con

1 reference

12 December 2020

Epoetin requirements predict mortality in hemodialysis patients

1 reference

12 December 2020

Hematocrit levels and hospitalization risks in hemodialysis patients.

1 reference

12 December 2020

Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement

1 reference

12 December 2020

Hematocrit level and associated mortality in hemodialysis patients

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRNEPH.2013.21

1 reference

28 August 2017

1 reference

PubMed ID

23438972